Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Condition:   Persistent Asthma
Interventions:   Drug: Fluticasone propionate Multidose Dry Powder Inhaler (Fp MDPI);   Drug: Fluticasone propionate /salmeterol MDPI (FS MDPI);   Drug: Fluticasone propionate HFA Inhalation Aerosol;   Drug: Fluticasone propionate/salmeterol dry powder formulation
Sponsors:   Teva Pharmaceutical Industries;   Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting – verified June 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days